5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)quinoxalin-6-amine: Selective α2-adrenergic Receptor Agonist for Immune Modulation Research

Executive Summary: 5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)quinoxalin-6-amine (B3465) is a selective α2-adrenergic receptor (α2-AR) agonist with high purity (98–99.88%) verified by HPLC and NMR (APExBIO product page). It is DMSO-soluble (≥25.7 mg/mL, ultrasonic-assisted) but insoluble in water and ethanol. This compound enables mechanistic studies of α2-AR signaling in immune modulation and is validated in post-surgery osteosarcoma recurrence models (Pei et al., 2025). APExBIO provides rigorous quality control, and the product is for research use only, not for clinical or diagnostic purposes.

Biological Rationale

α2-adrenergic receptors (α2-ARs) are G protein-coupled receptors (GPCRs) that modulate neurotransmitter release and vascular tone (NCBI Bookshelf). Selective activation of α2-ARs can suppress immune rejection responses, as demonstrated in models of post-surgical osteosarcoma recurrence (Pei et al., 2025). 5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)quinoxalin-6-amine is a small molecule designed for high specificity toward α2-ARs, minimizing off-target effects. The need for such compounds arises from limitations and resistance encountered with immune checkpoint blockade therapies in oncology (Pei et al., 2025).

Mechanism of Action of 5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)quinoxalin-6-amine

5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)quinoxalin-6-amine binds selectively to α2-adrenergic receptors, inducing conformational changes that activate Gi/o proteins. This leads to downstream inhibition of adenylyl cyclase, reduced cyclic AMP (cAMP) production, and modulation of ion channel activity (NCBI Bookshelf). In immune cells, α2-AR activation suppresses pro-inflammatory cytokine production and supports CD8+ T cell activation via TCR signaling enhancement (Pei et al., 2025). Proteomic studies highlight ITGAL as a central node in the regulatory network, with involvement of MSN and TOLLIP proteins associated with improved immune response (Pei et al., 2025).

Evidence & Benchmarks

• High-purity (98–99.88%) 5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)quinoxalin-6-amine verified by HPLC and NMR is available from APExBIO (product page).
• In vitro experiments show that the compound does not significantly affect viability, migration, or invasion of osteosarcoma cell lines (K7M2, 143b, Khos) under standard cell culture conditions (Pei et al., 2025, DOI).
• In vivo, hydrogel-delivered α2-AR agonist (UK14,304) significantly reduces post-surgical osteosarcoma recurrence in immunocompetent BALB/c mice (Pei et al., 2025, DOI).
• Proteomic and bioinformatic analyses reveal enhanced CD8+ T cell infiltration and TCR signaling, with key regulatory proteins (ITGAL, MSN, TOLLIP) implicated (Pei et al., 2025, DOI).
• The compound is DMSO soluble at ≥25.7 mg/mL (ultrasonic-assisted), but is insoluble in water and ethanol (APExBIO).
• Shipping on blue ice and storage at -20°C are required to maintain stability and purity (APExBIO, product page).

For additional mechanistic context, see the article "Unlocking the Translational Potential of Selective α2-Adrenergic Receptor Agonists"—this article updates the translational perspective by focusing on immunological endpoints and hydrogel delivery strategies. For DMSO-solubility details and high-purity sourcing, this resource provides protocol-level specificity, while the present article integrates new in vivo immunomodulatory data.

Applications, Limits & Misconceptions

5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)quinoxalin-6-amine is applied in:

• Selective α2-AR signaling pathway research, especially in oncology and immunology models.
• Studying immune rejection modulation in post-surgical osteosarcoma recurrence (Pei et al., 2025).
• Neuroscience receptor modulation studies.

Limits:

• Not for diagnostic or therapeutic human use (APExBIO, product page).
• Stability concerns necessitate immediate use after solution preparation.
• Insolubility in water and ethanol constrains some experimental protocols.

Common Pitfalls or Misconceptions

• Misconception: Suitable for direct in vivo injection in aqueous buffers. Fact: Compound is insoluble in water; requires DMSO or compatible hydrogel carrier.
• Misconception: Functions as a general adrenergic agonist. Fact: Compound is selective for α2-AR; minimal activity at β-adrenergic or other GPCRs (Mechanistic review).
• Pitfall: Exposing compound to room temperature for extended periods. Fact: Stability is compromised; always store at -20°C.
• Misconception: Direct cytotoxicity is the main anti-tumor effect. Fact: In vitro shows minimal cytotoxicity; immune modulation is primary mechanism (Pei et al., 2025).
• Pitfall: Use beyond research context. Fact: Product is not approved for clinical or diagnostic use (APExBIO, product page).

Workflow Integration & Parameters

For experimental use, dissolve the compound in DMSO (≥25.7 mg/mL with ultrasonic assistance). Prepare fresh solutions immediately before use. Store aliquots at -20°C (APExBIO). For in vivo delivery, incorporate into PLGA-PEG-PLGA hydrogels for sustained release, as validated in murine osteosarcoma models (Pei et al., 2025). Monitor for precipitation and verify compound integrity by HPLC if possible.

Conclusion & Outlook

5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)quinoxalin-6-amine is a rigorously validated, selective α2-adrenergic receptor agonist for advanced receptor signaling research. Its robust immune-modulatory properties in post-surgical osteosarcoma recurrence models position it as a critical tool for translational immunology (Pei et al., 2025). APExBIO ensures high purity and supply chain transparency. Continued research will clarify its role in additional immune and neurological contexts. For detailed product information, visit the APExBIO 5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)quinoxalin-6-amine page.